Koning Begins FDA Clinical Screening Trial

Koning will begin a US Food and Drug Administration (FDA) screening trial this month for their no-compression, Isotropic, 3-dimensional breast imaging device. The company received FDA PMA approval for commercial, diagnostic use in 2017. Since then, the Koning Breast CT (KBCT) has been installed in clinics and universities in the US and globally.

“This FDA screening trial is a major milestone for radiologists and patients,” says Koning President, David Georges. “An FDA cleared screening indication will allow clinics to perform breast exams with more clarity and it will permit millions of patients around the world to go into their breast imaging exams with confidence that their results will be accurate. We are proud to be the only no-compression, true 3D breast imaging device manufacturer that already has FDA diagnostic approval; this screening trial gives us even more momentum in our push to improve breast health for all women.

The trial was set to begin on November 1, 2021, with submission to the FDA in Q1 2022. The kickoff of the trial starts as Breast Cancer Awareness Month comes to an end and brings more awareness to the need for better breast imaging options for women everywhere.